why choose us

Clinical Trials Search

Showing 4,850 of 132,656 result(s)
Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib

Status: COMPLETED

Condition: Drug Kinetics

Interventions:

  1. Brand name;manufacturer: Supect Cap.;IL-YANG PHARM.
    Co., Ltd.
  2. Active ingredient: radotinib HCl 106.8mg (100mg as radoti

    Date: 2024-05-29

First Human Trial of Targeting MDM2;MDMX PET Imaging

Status: COMPLETED

Condition: MDM2;MDMX Gene Mutation

Interventions:

Utilizing a peptide with high affinity to MDM2;MDMX as the targeting moiety for radiopharmaceuticals, this study explores the diagnostic effic

Date: 2024-05-29

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

Status: COMPLETED

Condition: Healthy

Interventions: Administered orally

Date: 2024-05-29

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

Status: COMPLETED

Condition: Healthy

Interventions: Administered orally

Date: 2024-05-29

Clinical Variables and Dyspnea and Fear of Movement in Chronic Obstructive Pulmonary Patients

Status: COMPLETED

Condition: COPD

Interventions: Kinesiophobia Level Due to Dyspnea

Date: 2024-05-29

Phase I PK Study of Budesonide;Albuterol Delivered From PT027 in Healthy Chinese Participants.

Status: COMPLETED

Condition: Healthy Volunteer

Interventions: BDA MDI 160 ?g;180 ?g (single dose administered as 2 actuations of 80 ?g;90 ?g)

Date: 2024-05-29

Connective Tissue of Pectoralis Major Muscle: Anatomical Study

Status: COMPLETED

Condition: Tendon Injury - Upper Limb

Interventions: Through systematic ultrasound visualization of the pectoralis major muscle, we seek to directly visualize and characterize the different intra- and ex

Date: 2024-05-29

A Study to Evaluate the Effect of Povorcitinib on the QT;QTc Interval in Healthy Participants

Status: COMPLETED

Condition: Healthy Participants

Interventions: Povorcitinib will be administered at protocol defined dose.

Date: 2024-05-29